Heilongjiang ZBD Pharmaceutical Co Ltd (603567) fair value: what the stock is really worth
As of Oct 12, 2026: fair value of Heilongjiang ZBD Pharmaceutical Co Ltd ¥3.31, price ¥5.24, upside -36.8%, quality 47 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.
How to read this chart
60‑month range ¥4.28 – ¥18.89 · fair‑value band ¥2.72 – ¥4.29 · the ¥5.24 price screens above the ¥3.31 fair value. Dashed = 300-day average. As of Oct 2, 2026.
Follow Heilongjiang ZBD Pharmaceutical Co in your weekly email
Every Wednesday you see whether Heilongjiang ZBD Pharmaceutical Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese medicines in China. It offers cardiovascular and cerebrovascular, respiratory system, orthopedics, tumors, digestive system, anti-infection, mental nerve, genitourinary, and other disease fields.
Show more
Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese medicines in China. It offers cardiovascular and cerebrovascular, respiratory system, orthopedics, tumors, digestive system, anti-infection, mental nerve, genitourinary, and other disease fields. The company was founded in 1996 and is based in Hulin, China.
Stock analysis
Heilongjiang ZBD Pharmaceutical Co Ltd (603567) currently trades at ¥5.24, while our model-based Fair Value estimate is ¥3.31, 36.8% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of ¥4.48 per share, and 0 of the 9 models we run sit above the ¥5.24 price.
Bear case: the Dividend Discount group reads lowest at ¥2.46, and 9 of the 9 models stay below the price. Evidence for this calculation is low.
Scenario range: ¥2.72 (bear) to ¥4.29 (bull), the price of ¥5.24 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Spin-off in 2024: revenue and profit before it include the divested business. Growth is measured afresh from 2024.
Heilongjiang ZBD Pharmaceutical Co Ltd reported revenue of 798M CNY in FY2025 versus 4.1B CNY in FY2021, a compound −33.7%/yr. Reported net income was −1.4B CNY in FY2025.
Key figures
Market cap 4.9B CNY (≈ $737M) · P/S ratio 13.0 · EPS (TTM) ¥−1.66 · Dividend yield 5.6% · Return on equity −22.7% · Return on assets (EBIT) 2.1% · Operating margin −54.2% · Revenue (TTM) 379M CNY.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (medium confidence).
What moves the price
The share trades about 57% below its 52-week high and 22% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −22% fair-value upside, at −37%, 603567 screens richer than that median.
Fair Value models
Bear ¥2.72Fair Value ¥3.31Bull ¥4.29
Price ¥5.24 · Upside -36.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.55/100
Spin-off in 2024: revenue and profit before it include the divested business. Growth is measured afresh from 2024.
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
15.0% (2020) → −52.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+11.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +10.1% a year for the price.
Compare Heilongjiang ZBD Pharmaceutical Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 591 stocks
Beats the industry median on 5/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score47 · Below median
Fair Value upside−36.8% · Below median
Profitability
Return on assets−7.6% · Bottom 25%
Net margin (TTM)−171.2% · Bottom 25%
Operating margin (TTM)−54.2% · Bottom 25%
Growth and dividend
Revenue growth−53.5% · Bottom 25%
Dividend yield (TTM)5.6% · Top 25%
Balance sheet
Debt / equity0.01× · Lowest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/B0.12× · Cheapest 25%
P/S (TTM)1.95× · Cheaper than median
P/FCF2.9× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 19
FUTURE (revenue growth)0· sector 25
PAST (return on equity)0· sector 27
HEALTH (low debt)100· sector 96
DIVIDEND (yield)100· sector 31
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Heilongjiang ZBD Pharmaceutical Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/603567
Frequently asked questions
Is Heilongjiang ZBD Pharmaceutical Co Ltd (603567) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of ¥3.31 versus a price of ¥5.24, about −37% upside (overvalued).
What is the fair value of 603567?
Our model-based fair value for Heilongjiang ZBD Pharmaceutical Co Ltd is ¥3.31 (as of Oct 2, 2026), built from audited fundamentals. The current price: ¥5.24.
What is the quality score of 603567?
Heilongjiang ZBD Pharmaceutical Co Ltd has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Heilongjiang ZBD Pharmaceutical Co Ltd (603567)?
Our model-based price target is the fair value of ¥3.31 (as of Oct 2, 2026) from 9 valuation models. Cautious scenario ¥2.72, optimistic scenario ¥4.29. It is a calculation from audited fundamentals, not an analyst target.
What is the Heilongjiang ZBD Pharmaceutical Co Ltd stock forecast for 2026?
Our models put fair value at ¥3.31, about −37% upside versus a price of ¥5.24 (overvalued). Cautious scenario ¥2.72, optimistic scenario ¥4.29. The calculation is refreshed regularly with new filings.
What is the revenue of Heilongjiang ZBD Pharmaceutical Co Ltd (603567)?
Heilongjiang ZBD Pharmaceutical Co Ltd reported trailing-twelve-month revenue of about 379M CNY (latest available figure, as of Oct 2, 2026).
Does Heilongjiang ZBD Pharmaceutical Co Ltd pay a dividend?
Heilongjiang ZBD Pharmaceutical Co Ltd currently shows a dividend yield of about 5.59% relative to its recent price (as of Oct 2, 2026).
What growth is priced into Heilongjiang ZBD Pharmaceutical Co Ltd (603567)?
For today's price to be fair in a discounted-cash-flow model, Heilongjiang ZBD Pharmaceutical Co Ltd would have to grow free cash flow by +11.9 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -25.2 % per year. As of Oct 2, 2026.
What discount rate (WACC) does the fair value of 603567 use?
Our models discount Heilongjiang ZBD Pharmaceutical Co Ltd at 10.4 %: a base by market capitalisation (small), damped by beta 0.20, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Heilongjiang ZBD Pharmaceutical Co Ltd that is +11.9 % per year a year over ten years, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has Heilongjiang ZBD Pharmaceutical Co Ltd (603567) delivered so far?
Over the past 5 years revenue at Heilongjiang ZBD Pharmaceutical Co Ltd grew -25.2 % a year. The price currently implies +11.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Heilongjiang ZBD Pharmaceutical Co Ltd (603567) growing?
The median revenue growth in the sector is +5.3 % a year. That is the yardstick for the growth priced into Heilongjiang ZBD Pharmaceutical Co Ltd (+11.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Heilongjiang ZBD Pharmaceutical Co Ltd (603567)?
The free-cash-flow yield on the price is 5.14 %: that much free cash flow Heilongjiang ZBD Pharmaceutical Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Heilongjiang ZBD Pharmaceutical Co Ltd (603567)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Heilongjiang ZBD Pharmaceutical Co Ltd it is ¥3.31 per share (as of Oct 2, 2026), against a price of ¥5.24. It is the blended result of 9 valuation models (cash flow, earnings, asset, dividend).
Is Heilongjiang ZBD Pharmaceutical Co Ltd stock overvalued or undervalued in 2026?
As of Oct 2, 2026, 603567 trades above its calculated fair value: price ¥5.24, fair value ¥3.31, a gap of about −37% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 603567?
No. The price is what the market pays today (¥5.24); the fair value is what the company's own numbers justify (¥3.31). For Heilongjiang ZBD Pharmaceutical Co Ltd the two are ¥1.93 per share apart. That gap is exactly why we show both numbers side by side.
How much is Heilongjiang ZBD Pharmaceutical Co Ltd worth?
The market values Heilongjiang ZBD Pharmaceutical Co Ltd at about 4.9B CNY (market capitalisation, as of Oct 2, 2026). Per share that is ¥5.24; our models calculate a fair value of ¥3.31 per share.
What do the bullish and bearish scenarios say about 603567?
Our models span a range for Heilongjiang ZBD Pharmaceutical Co Ltd: cautious scenario ¥2.72, base ¥3.31, optimistic ¥4.29 per share (as of Oct 2, 2026, price ¥5.24). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Heilongjiang ZBD Pharmaceutical Co Ltd (603567)?
Balance-sheet figures for Heilongjiang ZBD Pharmaceutical Co Ltd (as of Oct 2, 2026): return on equity −22.7%, debt of 0.01 per unit of equity. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is 603567 from its 52-week high?
Heilongjiang ZBD Pharmaceutical Co Ltd trades at ¥5.24, about 57% below its 52-week high of ¥12.08 and 22% above the low of ¥4.28 (as of Oct 12, 2026). Distance from the high says nothing about value: that is what the fair value of ¥3.31 is for.
Which stocks are comparable to Heilongjiang ZBD Pharmaceutical Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Heilongjiang ZBD Pharmaceutical Co Ltd stock attractive at the current price?
The data as of Oct 2, 2026: price ¥5.24, calculated fair value ¥3.31 (−37%), Quality Score 47/100, from 9 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 603567 calculated?
We run Heilongjiang ZBD Pharmaceutical Co Ltd through 9 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥3.31, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Heilongjiang ZBD Pharmaceutical Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Heilongjiang ZBD Pharmaceutical Co Ltd (603567)?
The closing price on Oct 12, 2026 was ¥5.24. Our model-based fair value is ¥3.31, about −37% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Heilongjiang ZBD Pharmaceutical Co Ltd right now?
The price sits above even our optimistic bull case (¥4.29). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of Heilongjiang ZBD Pharmaceutical Co Ltd (603567) come from?
Earnings per share at Heilongjiang ZBD Pharmaceutical Co Ltd grew −6.0 % a year from 2013 to 2024. Broken into its drivers: revenue per share +5.0 %, EBIT margin −9.9 %, tax rate +0.0 %, residual (interest, one-offs) −0.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Heilongjiang ZBD Pharmaceutical Co Ltd
How large is the market capitalisation of Heilongjiang ZBD Pharmaceutical Co Ltd (603567)?
The market capitalisation of Heilongjiang ZBD Pharmaceutical Co Ltd is 4.9B CNY (≈ $737M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Heilongjiang ZBD Pharmaceutical Co Ltd (603567)?
The price-to-sales ratio of Heilongjiang ZBD Pharmaceutical Co Ltd is 13.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Heilongjiang ZBD Pharmaceutical Co Ltd (603567)?
Earnings per share at Heilongjiang ZBD Pharmaceutical Co Ltd are ¥−1.66. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Heilongjiang ZBD Pharmaceutical Co Ltd (603567)?
The dividend yield of Heilongjiang ZBD Pharmaceutical Co Ltd is 5.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the return on equity of Heilongjiang ZBD Pharmaceutical Co Ltd (603567)?
The return on equity (ROE) of Heilongjiang ZBD Pharmaceutical Co Ltd is −22.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Heilongjiang ZBD Pharmaceutical Co Ltd (603567)?
On an EBIT basis the return on assets of Heilongjiang ZBD Pharmaceutical Co Ltd is 2.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Heilongjiang ZBD Pharmaceutical Co Ltd (603567)?
The operating margin of Heilongjiang ZBD Pharmaceutical Co Ltd is −54.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Heilongjiang ZBD Pharmaceutical Co Ltd (603567)?
Revenue at Heilongjiang ZBD Pharmaceutical Co Ltd is growing −53.5% versus a year earlier (3y avg −42.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Heilongjiang ZBD Pharmaceutical Co Ltd (603567)?
Earnings per share at Heilongjiang ZBD Pharmaceutical Co Ltd are growing −74.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Heilongjiang ZBD Pharmaceutical Co Ltd (603567) carry?
The net debt of Heilongjiang ZBD Pharmaceutical Co Ltd is 1.3B CNY (fiscal year 2025, ≈ 5.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Heilongjiang ZBD Pharmaceutical Co Ltd in the live analysis
One click puts Heilongjiang ZBD Pharmaceutical Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
